Full disclaimer VENTURE Phase 2 Results: What the Data Shows Viking Therapeutics presented full data from the Phase 2 VENTURE-Oral Dosing trial at the European Congress on Obesity (ECO) in May 2026
How are they given
Peterson LR, Saeed IM, McGill JB, Herrero P, Schechtman KB, Gunawardena R, Recklein CL, Coggan AR, Demoss AJ, Dence CS, et al
Xin Lu, [email protected] These authors have contributed equally to this work ORCID: Zixuan Hu, orcid.org/0009-0000-7508-5457
24, 25 In agreement with previous studies, 25 weight loss in all groups increased concentrations of adiponectin and reduced fibrinogen levels
A professional Semaglutide API manufacturer in India ensures high purity levels through advanced synthesis technology, strict quality control, multi-stage purification, and regulatory-grade documentation